Rule Breaker. As long as I live, I'll never forget the day I heard those two words.
It was Christmas 1999. I was catching up with an old pal on the phone. That summer, he'd tipped me to a local scientist who was boasting he could crack the human genome. There was an IPO. I bought a little and forgot it.
What the heck is going on here?
Sure, biotech was blowing up. Amgen
By New Year's, my genome stock seemed to be doubling every week. As it turns out, some Fool named David Gardner had bought it for his online "Rule Breaker" portfolio. In December 1999, I had no idea what those two words meant, but I was going to find out. This guy was moving the market.
You may have heard that Rule Breaker investing is back. But I warn you, it's probably not what you think. It's certainly not what I thought it was when I heard those two words in December 1999.
For one thing, it's not all tech
Yes, there was some technology in the original Rule Breaker portfolio. But as it turns out, it's not so much disruptive technologies David Gardner and his "Rule Breaker" disciples were after as disruptive businesses. I'll explain.
Hardly high tech, right? But you know what really made Starbucks a Rule Breaker in 1998? There was no precursor and no second fiddle. If you bought Starbucks along with David in 1998, congratulations: You're a Rule Breaker, too.
So just what makes a Rule Breaker investor?
To find out, I caught up with David Gardner himself and asked him. His reply might surprise you: "It's an investor who can embrace the contrary nature of paying up for great growth stocks." This is an important point.
As David points out, great growth companies rarely look "cheap," at least when measured by traditional valuation metrics. So you have to pay up. That takes guts, but Rule Breakers can be worth the gamble. Should you take David's word for it? I would.
When David shuttered his real-money Rule Breaker portfolio, he'd managed a 20.1% annualized return. That was in mid-2003, after the bear market. Compare that with 9.1% for the S&P 500 and 7.3% for the Nasdaq over the same period. That kind of performance over 10 years made a legend of Peter Lynch, and rightfully so.
This stuff is not for everyone
Growth investing can get hairy, especially in markets like this. I learned that myself when the genome stocks blew up in 2000, and more recently when David and his team recommended another biotech, Encysive Pharmaceuticals, and were forced to sell it at a loss.
Then again, Vertex Pharmaceuticals
The trick, of course, is spotting opportunities like these and having the guts to buy when you do. It certainly helps to get your information (and support) from someone you can trust -- someone who does the legwork. In other words, not from some wahoo on the phone.
So, why not go straight to the source?
Listen, I know it's tough out there. That's why I want you to accept a 30-day free trial to David Gardner's Motley Fool Rule Breakers newsletter. That way, you can sample the complete service, and you won't have to spend a lot of money to see what David and his team of analysts are looking at now.
You can even read all back issues and cherry-pick every active and past pick for free during your one-month trial. Of course, there's never any pressure to subscribe. If you don't like what you see, you don't pay a cent.
I can't say you'll get rich quick if you accept. But I can promise that you'll get some great ideas, hear about some great new technologies, and that you have nothing to lose. If you think you're up to it and want to learn more about taking a free trial, click here.
This article was originally published Dec. 16, 2004. It has been updated.
Paul Elliott does not own shares of any companies mentioned. Starbucks is a Motley Fool Stock Advisor recommendation. Starbucks and Dell are Inside Value recommendations. Vertex is a Rule Breakers selection. Eli Lilly is a former Income Investor pick. You can view all the Rule Breakers picks with your free trial. The Motley Fool owns shares of Starbucks and has a disclosure policy.